Acumen Pharmaceuticals (ABOS) Assets Average (2021 - 2026)

Acumen Pharmaceuticals (ABOS) has 6 years of Assets Average data on file, last reported at $128.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 42.17% year-over-year to $128.2 million; the trailing twelve-month figure through Mar 2026 stood at $128.2 million (down 42.17% YoY), and the FY2025 full-year result was $180.9 million, down 34.11% from the prior year.
• Assets Average fell to $128.2 million in Q1 2026, from $132.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $305.5 million in Q1 2024 to a low of $128.2 million in Q1 2026.
• A 5-year average of $218.4 million and a median of $215.9 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average surged 61.49% in 2024 and tumbled 47.61% in 2025, its largest moves.
• Tracing ABOS's Assets Average over 5 years: stood at $199.9 million in 2022, then jumped by 49.18% to $298.2 million in 2023, then dropped by 15.18% to $253.0 million in 2024, then tumbled by 47.61% to $132.5 million in 2025, then fell by 3.24% to $128.2 million in 2026.
• Business Quant data shows ABOS's Assets Average at $128.2 million in Q1 2026, $132.5 million in Q4 2025, and $157.1 million in Q3 2025.